Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
Roshini Claire Anthony, 19 hours ago

The presence of pulmonary arterial hypertension (PAH) in individuals with systemic sclerosis is associated with an increased mortality risk, a study from Singapore showed.

23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
09 Jan 2020
Acute ischaemic stroke patients who are current or recent smokers are at greater odds of having unfavourable functional outcomes 3 months after the index event, a study has found.

Ticagrelor monotherapy tied to lower all-cause death in patients undergoing multivessel PCI

22 Oct 2019

An experimental strategy of 1-month dual antiplatelet therapy (DAPT) followed by long-term ticagrelor monotherapy (23 months) shows a favourable balance of ischaemia and bleeding risks in patients who undergo multivessel percutaneous coronary intervention (PCI), according to a recent study.

“Data on optimal antiplatelet treatment regimens in patients who undergo multivessel PCI are sparse,” the authors said.

To address this problem, a prospective, multicentre, open-label, randomized controlled trial was conducted. The authors randomly assigned patients 1:1 to either the experimental strategy (1-month DAPT followed by 23-month ticagrelor) or the reference regimen (12-month DAPT followed by 12-month aspirin monotherapy).

The primary endpoint was the composite of all-cause death or new Q-wave myocardial infarction at 2 years, and the secondary endpoint was Bleeding Academic Research Consortium type 3 or 5 bleeding.

Of the 15,845 patients identified, 3,576 (22.4 percent) with multivessel PCI had a significantly higher risk of ischaemic and bleeding events at 2 years compared to those with single-vessel PCI.

An interaction was observed on the primary endpoint between the experimental strategy and multivessel PCI (hazard ratio [HR], 0.62, 95 percent CI, 0.44–0.88; p-interaction=0.031), with the difference primarily driven by a lower risk of all-cause death.

On the other hand, the two regimens demonstrated statistically similar risk of Bleeding Academic Research Consortium type 3 or 5 bleeding (HR, 0.92, 0.61–1.39; p-interaction=0.754).

“These findings should be interpreted as hypothesis-generating and need to be replicated in future dedicated randomized trials,” the authors said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
Roshini Claire Anthony, 19 hours ago

The presence of pulmonary arterial hypertension (PAH) in individuals with systemic sclerosis is associated with an increased mortality risk, a study from Singapore showed.

23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
09 Jan 2020
Acute ischaemic stroke patients who are current or recent smokers are at greater odds of having unfavourable functional outcomes 3 months after the index event, a study has found.